180 related articles for article (PubMed ID: 23146151)
21. The Management of Patients With Idiopathic Pulmonary Fibrosis.
Spagnolo P; Tzouvelekis A; Bonella F
Front Med (Lausanne); 2018; 5():148. PubMed ID: 30013972
[TBL] [Abstract][Full Text] [Related]
22. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
[TBL] [Abstract][Full Text] [Related]
23. Update on therapeutic management of idiopathic pulmonary fibrosis.
Tzouvelekis A; Bonella F; Spagnolo P
Ther Clin Risk Manag; 2015; 11():359-70. PubMed ID: 25767391
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
25. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
[TBL] [Abstract][Full Text] [Related]
26. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
[TBL] [Abstract][Full Text] [Related]
27. Nintedanib-induced glomerular microangiopathy: a case report.
Hasegawa M; Uehara A; Suzuki T; Sekine R; Yazawa M; Ichikawa D; Koike J; Shibagaki Y
CEN Case Rep; 2020 Nov; 9(4):295-300. PubMed ID: 32279192
[TBL] [Abstract][Full Text] [Related]
28. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
29. [Expert Knowledge and Supporting Advice for the Clinical Use of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis].
Behr J; Günther A; Kreuter M; Koschel D; Prasse A; Pfeifer M; Costabel U
Pneumologie; 2017 Sep; 71(9):567-579. PubMed ID: 28772332
[TBL] [Abstract][Full Text] [Related]
30. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.
Epstein Shochet G; Bardenstein-Wald B; McElroy M; Kukuy A; Surber M; Edelstein E; Pertzov B; Kramer MR; Shitrit D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805152
[TBL] [Abstract][Full Text] [Related]
32. Idiopathic pulmonary fibrosis: exploring the clinical and economic implications of the evolving treatment landscape.
de Andrade JA; Owens GM; Tolle L
Am J Manag Care; 2021 May; 27(7 Suppl):S131-S137. PubMed ID: 34003616
[TBL] [Abstract][Full Text] [Related]
33. The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.
Koyama K; Goto H; Morizumi S; Kagawa K; Nishimura H; Sato S; Kawano H; Toyoda Y; Ogawa H; Homma S; Nishioka Y
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):478-487. PubMed ID: 30540913
[TBL] [Abstract][Full Text] [Related]
34. VEGFR1-tyrosine kinase signaling in pulmonary fibrosis.
Amano H; Matsui Y; Hatanaka K; Hosono K; Ito Y
Inflamm Regen; 2021 Jun; 41(1):16. PubMed ID: 34082837
[TBL] [Abstract][Full Text] [Related]
35. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
36. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
[TBL] [Abstract][Full Text] [Related]
37. Profile of nintedanib in the treatment of solid tumors: the evidence to date.
Awasthi N; Schwarz RE
Onco Targets Ther; 2015; 8():3691-701. PubMed ID: 26677336
[TBL] [Abstract][Full Text] [Related]
38. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
40. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
Spagnolo P; Maher TM; Richeldi L
Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
